Joint Ventures Recaps Influential EULAR Studies in SLE, RA, and More ByRihards Buss, MD,Jack Arnold, MBBS, MRCP, PhDJuly 16th 2026
Joint Ventures: Aiming for Targeted First-Line Therapy in Early RA at EULAR 2026ByJack Arnold, MBBS, MRCP, PhD,Laurence Duquenne, MD, PhDJune 23rd 2026
Fibroblast TGFβ Signaling in Vascular Niches May Drive Treatment-Refractory RA, With Kevin Wei, MD, PhDByKevin Wei, MD, PhDApril 23rd 2026
Abatacept May Delay RA Onset for Up to 4 Years in At-Risk Individuals, With Andrew Cope, MD, PhDByAndrew Cope, MDApril 20th 2026
Precision Medicine and the Pursuit of Remission in RA and PsA, with Arthur Kavanaugh, MDByArthur Kavanaugh, MDFebruary 20th 2026